Native Human Immunoglobulin G2 (IgG2) Protein

Name: Native Human Immunoglobulin G2 (IgG2) Protein
Brand: Beta LifeScience
SKU: BAR-0095P
Price: 165.0 USD
Availability: InStock

Collections: All products, Native proteins

Price

Size

100ug

Quantity

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Human Immunoglobulin G2 (IgG2) is a 146 kDa protein. Serum IgG2 constitutes approximately 23% of total immunoglobulin G and is distinguished by a truncated 12-amino-acid hinge region with a poly-proline helix stabilized by four interchain disulfide bonds. This rigid structure limits Fab arm flexibility, reducing Fcγ receptor (FcγR) binding and complement activation compared to IgG1/IgG3. However, IgG2 excels in targeting repetitive carbohydrate antigens on encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae, forming high-avidity interactions critical for polysaccharide immunity. Its Fc domain binds FcγRIIA-H131 with moderate affinity, enabling phagocyte-mediated pathogen clearance in specific contexts. Deficiency in IgG2 (<2.1 g/L) impairs anti-polysaccharide responses, increasing susceptibility to recurrent sinopulmonary infections and invasive bacterial diseases. This deficiency often coexists with IgG4 or IgA deficits, complicating immune competence. Clinically, serum IgG2 quantification aids in evaluating humoral function, particularly in patients with chronic infections or hypogammaglobulinemia. Therapeutically, IgG2’s reduced Fc-mediated effector functions are exploited in oncology. Panitumumab, an IgG2 anti-EGFR monoclonal antibody, minimizes cytokine release syndrome while retaining tumor-targeting efficacy. Its inefficient FcRn-mediated transcytosis-attributed to the absence of Gly236 in the hinge-also results in lower placental transfer (~50% maternal levels), reducing fetal exposure risks. Emerging engineering strategies leverage IgG2’s structural stability for prolonged serum half-life and minimized off-target activation, enhancing therapeutic safety profiles.
Source	Human Plasma
Form	Frozen
Buffer	Frozen in 20 mM sodium phosphate, pH 7.4, with 150 mM NaCl and 0.05% NaN₃
Purity	Greater than 95% as determined by SDS-PAGE.
Molecular Weight	146 kDa
Protein Determination	Extinction Coefficient (E) = 1.36 (0.1% at 280 nm, 1 cm pathway)
Storage/Handling	≤ -20°C

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Native Human Immunoglobulin G2 (IgG2) Protein

Native Human Immunoglobulin G2 (IgG2) Protein

Product Overview

FAQs